On May 11, a Canadian medical company, Biolyse, signed an agreement with the Bolivian government to manufacture and export patented COVID-19 vaccines if Canada grants them a compulsory licence. Biolyse’s efforts will once again test the capacity of Canada’s Access to Medicines Regime to respond to global health needs as it was ostensibly intended to do. Hear from the company and experts on CAMR and how the Biolyse–Bolivia vaccines deal relates to efforts at the WTO to agree on a temporary waiver on intellectual property rights for COVID-19 vaccines and treatments.
– John R. Fulton, President of BioNiagara and project partner/consultant and spokesperson for Biolyse Pharma Corporation
– Arianna Schouten, Researcher, Knowledge Ecology International
– Richard Elliott, Executive Director, HIV Legal Network
Event sponsored by the Trade Justice Network and Canadian Centre for Policy Alternatives.